These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 20457704)

  • 1. Sirolimus and tuberous sclerosis-associated renal angiomyolipomas.
    Krischock L; Beach R; Taylor J
    Arch Dis Child; 2010 May; 95(5):391-2. PubMed ID: 20457704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumoral activity of rapamycin in renal angiomyolipoma associated with tuberous sclerosis complex.
    Wienecke R; Fackler I; Linsenmaier U; Mayer K; Licht T; Kretzler M
    Am J Kidney Dis; 2006 Sep; 48(3):e27-9. PubMed ID: 16931204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-dose rapamycin reduces kidney volume angiomyolipomas and prevents the loss of renal function in a patient with tuberous sclerosis complex.
    Peces R; Peces C; Cuesta-López E; Pérez-Dueñas V; Vega-Cabrera C; Azorín S; Selgas R
    Nephrol Dial Transplant; 2010 Nov; 25(11):3787-91. PubMed ID: 20663789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of rapamycin on angiomyolipomas in patients with tuberous sclerosis.
    Cabrera López C; Martí T; Catalá V; Torres F; Mateu S; Ballarín Castán J; Torra Balcells R
    Nefrologia; 2011; 31(3):292-8. PubMed ID: 21629335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The mTOR inhibitor rapamycin significantly improves facial angiofibroma lesions in a patient with tuberous sclerosis.
    Hofbauer GF; Marcollo-Pini A; Corsenca A; Kistler AD; French LE; Wüthrich RP; Serra AL
    Br J Dermatol; 2008 Aug; 159(2):473-5. PubMed ID: 18547304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tuberous sclerosis complex-associated angiomyolipomas: focus on mTOR inhibition.
    Budde K; Gaedeke J
    Am J Kidney Dis; 2012 Feb; 59(2):276-83. PubMed ID: 22130643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regression of renal angiomyolipomas with oral rapamycin therapy in a patient with tuberous sclerosis complex disease.
    Torun D; Micozkadioglu H; Gedikoglu M; Ozelsancak R; Tekkarismaz N
    Saudi J Kidney Dis Transpl; 2019; 30(2):545-548. PubMed ID: 31031395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sirolimus therapy for fibromatosis and multifocal renal cell carcinoma in a child with tuberous sclerosis complex.
    Pressey JG; Wright JM; Geller JI; Joseph DB; Pressey CS; Kelly DR
    Pediatr Blood Cancer; 2010 Jul; 54(7):1035-7. PubMed ID: 20108343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors.
    Kenerson HL; Aicher LD; True LD; Yeung RS
    Cancer Res; 2002 Oct; 62(20):5645-50. PubMed ID: 12384518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CT characteristics predict the response to everolimus or sirolimus of renal angiomyolipomas in patients with tuberous sclerosis complex.
    Wang W; Guo H; Shi B; Sun H; Li H; Zhang Y; Cai Y
    Int Urol Nephrol; 2019 Apr; 51(4):671-676. PubMed ID: 30756282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of mTOR inhibition in the treatment of patients with renal angiomyolipomas.
    Coombs EJ
    J Am Assoc Nurse Pract; 2013 Nov; 25(11):588-96. PubMed ID: 24170533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Rapamycin in the treatment of renal diseases associated with tuberous sclerosis complex].
    Dun S; Zou LP; Zhang MN; Wang YY; He W; Chen HM; Hu LY; Chen XQ; Lu Q; Pang LY; Liu LY; Tang LN; Wang B
    Zhonghua Er Ke Za Zhi; 2019 Nov; 57(11):852-856. PubMed ID: 31665839
    [No Abstract]   [Full Text] [Related]  

  • 13. Rapamycin as a therapy of choice after renal transplantation in a patient with tuberous sclerosis complex.
    Tarasewicz A; Debska-Slizień A; Konopa J; Zdrojewski Z; Rutkowski B
    Transplant Proc; 2009 Nov; 41(9):3677-82. PubMed ID: 19917366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Huge renal angiomyolipomas in tuberous sclerosis complex.
    Chan SY; Chan WK
    Nephrology (Carlton); 2005 Aug; 10(4):382-6. PubMed ID: 16109086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and molecular insights into tuberous sclerosis complex renal disease.
    Siroky BJ; Yin H; Bissler JJ
    Pediatr Nephrol; 2011 Jun; 26(6):839-52. PubMed ID: 21152937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renal angiomyolipoma: clinicopathologic study of 194 cases with emphasis on the epithelioid histology and tuberous sclerosis association.
    Aydin H; Magi-Galluzzi C; Lane BR; Sercia L; Lopez JI; Rini BI; Zhou M
    Am J Surg Pathol; 2009 Feb; 33(2):289-97. PubMed ID: 18852677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conservative management of giant symptomatic angiomyolipomas in patients with the tuberous sclerosis complex.
    Danforth TL; Lane BR; Novick AC
    BJU Int; 2007 Oct; 100(4):794-7. PubMed ID: 17590180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microscopic Kidney Disease in Tuberous Sclerosis Complex and Treatment With mTOR Inhibition.
    Kronick J; Gabril MY; House AA
    Am J Kidney Dis; 2023 Dec; 82(6):772-775. PubMed ID: 37532078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metastatic breast carcinoma to renal angiomyolipomas in tuberous sclerosis.
    Williams TR; Oakes MF
    Urology; 2008 Feb; 71(2):352.e5-7. PubMed ID: 18308125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy of cannabidiol on renal angiomyolipoma and subependymal giant cell tumor volume in tuberous sclerosis complex.
    Barnett JR; Grinspoon RA; Harisinghani M; Caruso PA; Thiele EA
    J Clin Neurosci; 2020 Jul; 77():85-88. PubMed ID: 32409220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.